Pseudovirus News and Research

RSS

Study compares the neutralizing potential of antibodies against two Omicron variants

A new study investigates if the two SARS-CoV-2 Omicron variants BA.1 and BA.2 are comparable with respect to their ability to evade the host immunity induced by vaccination or prior infection.

9 Feb 2022

Induction and stability of vaccine-specific antibodies in multiple sclerosis patients on different disease-modifying therapies

Researchers have investigated the lack of response to treatment in certain multiple sclerosis patients.

9 Feb 2022

Memory B cells induced by mRNA vaccine may help generate antibodies against Omicron

In a recent research article published in the journal of Science Immunology, a team of researchers from Japan performed longitudinal analysis on the cellular composition of receptor-binding domain (RBD) memory B cell subsets and its antibody binding and neutralizing activity against the Beta, Delta, and Omicron variants following the second dose of a messenger ribonucleic acid (mRNA) vaccine.

8 Feb 2022

Novel, rapid and efficient assay for SARS-CoV-2 neutralizing antibodies

Researchers validate a quick, highly efficient, and automated assay to detect neutralizing antibodies against SARS-CoV-2.

7 Feb 2022

Booster dose of Pfizer-BioNTech COVID vaccine protects elderly against Omicron

Researchers discuss the impact of mRNA booster immunization on the neutralizing activity against the SARS-CoV-2 Omicron variant in the elderly.

6 Feb 2022

Evaluating effects of D614G and P681R/H mutations on SARS-CoV-2 VOCs

Researchers evaluate how the D614G and P681H mutations alter the attributes of SARS-CoV-2 VOCs.

3 Feb 2022

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

Researchers demonstrate that SARS-CoV-2 RBD-based nanoparticle vaccine induces neutralizing antibodies against SARS-CoV-2 variants.

2 Feb 2022

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

A large multinational group of researchers has shown how the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gained exceptional immune evasion properties but also a much lower propensity to enter cells such as those in lung alveoli, resulting in its reduced pathogenicity. Their paper is currently released as an unedited version of the manuscript prior to publication in the journal Nature.

1 Feb 2022

Exploring beta-coronavirus neutralization by vaccine-induced murine antibody WS6

In a new study, researchers evaluated the neutralizing antibody titers in mice vaccinated with messenger ribonucleic acid (mRNA) encoding SARS-CoV-2 spike (S) protein.

1 Feb 2022

Preliminary study assesses durability of NAb titers against Omicron after mRNA-1273 booster

Researchers from Moderna, the developers of one key vaccine, have been investigating its ability to protect against the Omicron variant.

31 Jan 2022

Children and adolescents respond as well or better than adults to mRNA-1273 COVID vaccination

A recent study assesses the neutralization efficacy of the mRNA-1273 vaccine against the SARS-CoV-2 Omicron variant in children, adolescents, and adults.

30 Jan 2022

Scientists evaluate zoonotic potential of NeoCoV, a coronavirus related to MERS-CoV

Researchers identify ACE2 as the functional receptor of the two close relatives of MERS-CoV, NeoCoV and PDF-2180-CoV, in bats.

30 Jan 2022

E406W mutation on SARS-CoV-2 RBD escapes monoclonal antibody cocktail-mediated neutralization

Researchers look to better understand the molecular basis of E406W-mediated escape from the REGEN-COV cocktail and cilgavimab.

28 Jan 2022

Targeting CHI3L1 inhibits SARS-CoV-2 variants, including Delta and Omicron

Researchers show that the CHI3L1 inhibitors reduce epithelial cell infection by SARS-CoV-2 VOC pseudovirus moieties.

27 Jan 2022

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

In a new study, a team of researchers developed a vaccine candidate with the SARS-CoV-2 spike (S) glycoprotein coated onto lipid vesicles which resembles virus-like particles.

26 Jan 2022

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.

24 Jan 2022

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

In a new study, researchers discuss the role of calcium signaling pathways as targets of inhibition in potential new antiviral therapeutic pathways for SARS-CoV-2.

20 Jan 2022

Study reports of receptor-binding domain multimer capable of enhancing the immune response against SARS-CoV-2

Researchers have discovered a new way to induce immunity against the RBD.

19 Jan 2022

Three doses Of Pfizer-BioNTech vaccine could offer sufficient level of protection from Omicron

A new study that evaluated the effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against the Omicron variant indicates that three doses could offer a sufficient level of protection from disease caused by the Omicron variant.

18 Jan 2022

Exploring SARS-CoV-2 Omicron variant’s neutralizing capacity of booster vaccines

In a new study, researchers analyzed the neutralization of SARS-CoV-2 Omicron and D614G variants before and after subjects received COVID-19 booster vaccinations.